BioSpace News Archive

Carcinoembryonic antigen (CEA) is a protein usually produced in developing fetus and disappears or is absent in adults. Production of abnormal amount of CEA protein could lead to cancer.

ViaDerma, Inc., is pleased to announce they are launching two new and improved formulas for its top selling product, Vitastem and Vitastem Ultra.

Polpharma Biologics Group announces that its joint venture company with Santo Holding, Bioeq, has received notification by the U.S. Food and Drug Administration that the biologics license application for its proposed biosimilar to Lucentis®, a blockbuster ophthalmological drug containing ranibizumab as active drug substance, has been accepted for review.

SQZ Biotechnologies, focused on unlocking the full potential of cell therapies for multiple therapeutic areas, announced that it will present updates across three oncology programs at various stages of development.

Madrigal Pharmaceuticals, a clinical-stage biopharmaceutical company pursuing novel therapeutics for fatty liver diseases, announces its support of the Fatty Liver Foundation, the leading patient advocacy organization focused on the diagnosis, treatment and support of Americans with non-alcoholic fatty liver disease, including non-alcoholic steatohepatitis.

Covis Pharma GmbH and Norgine B.V. announced data demonstrating the investigational anticoagulant reversal agent, ciraparantag, reverses the anticoagulant activity of apixaban and rivaroxaban in healthy elderly patients, were published in the European Heart Journal, official journal of the European Society of Cardiology.

ADMA Biologics, Inc. announced on-demand access to an exclusive educational event at IDWeek 2021 on respiratory viral infections, presented by nationally recognized clinical experts Dr. Michael Ison from Northwestern University and Dr. Jolan Walter from the University of South Florida and Johns Hopkins All Children’s Hospital.

Centene Corporation announced it plans to expand its Medicare Advantage offerings, offering its wide range of Medicare Advantage plans in 1,575 counties across 36 states during the 2022 Medicare Annual Enrollment Period.

C-RAD AB (NASDAQ Stockholm: CRAD B) and Accuray Incorporated (NASDAQ: ARAY) announced today they have signed an agreement designed to enhance the Accuray Radixact® System’s ability to treat breast cancer. The companies will partner to provide customers with a solution for deep inspiration breath hold (DIBH)* using the C-RAD Catalyst+ HD and Radixact System. DIBH is a technique frequently used for breast cancer treatments.

MannKind Corporation, a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced the enrollment of the first pediatric patient in the INHALE-1 study.